Digital Biotech on pre-clinical study for new anti-Arzheimer drug.

Published: 2006-09-20 06:52:00

Updated: 2006-09-20 06:52:00

Digital Biotech Inc. has launched a pre-clinical study for the new candidated drug in the treatment of Arzheimeer disease, The mode of the drug action blocks an aggregation of toxic protein called beta-amyloids and detoxifies the aggregated proteins found in the brain of the Arzheimer patients.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK